ReviewClinical ophthalmology (Auckland, N.Z.)2014
Managing adverse effects of glaucoma medications.
Review in Clinical ophthalmology (Auckland, N.Z.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 66 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prevalence of Ocular Surface Disease in Malaysian Glaucoma Patients
Personality Traits and Their Relation to Ocular Adverse Effects From Glaucoma Medications
Who cites it
66 citing papers in PubMed, 2 syntheses or guidelines pooled it, 162 citations in OpenAlex.
- Comparison of 360-Degree Trabeculotomy Versus Traditional Angle Surgery in Primary Congenital Glaucoma: A Systematic Review and Meta-Analysis.Journal of glaucoma · 2026Pooled it
- Anti-inflammatory treatment after selective laser trabeculoplasty: a systematic review of the literature and meta-analysis of randomized control trials.Arquivos brasileiros de oftalmologia · 2023Pooled it
- Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study.Japanese journal of ophthalmology · 2021Trial
- Brinzolamide/brimonidine fixed-dose combination bid as an adjunct to a prostaglandin analog for open-angle glaucoma/ocular hypertension.European journal of ophthalmology · 2021Trial
- Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study.Japanese journal of ophthalmology · 2020Trial
- Transcriptomic Study of Mechanism Driving Conjunctival Fibrosis Following Glaucoma Filtration Surgery.Biomedicines · 2026Article
- Conjunctival Vascular Metrics Using Automated Vessel Detection from Slit Lamp Images for Hyperemia Severity Assessment.Diagnostics (Basel, Switzerland) · 2026Article
- Intraocular pressure induced blood retinal barrier compromise in mouse models and human glaucoma.Nature communications · 2026Article
- rAAV prostaglandin-based gene therapy lowers intraocular pressure and preserves optic nerve health in glaucomatous DBA/2J mice.bioRxiv : the preprint server for biology · 2026Article
- Validating and updating the OHTS-EGPS model predicting 5-year glaucoma risk among patients with ocular hypertension using electronic medical records: a cohort study.Health technology assessment (Winchester, England) · 2026Article
- Effect of Combined Cataract and Minimally Invasive Glaucoma Surgeries on Glaucoma-Specific Quality of Life.Journal of clinical medicine · 2026Article
- Development of a conjunctival contact-type drug delivery device for latanoprost using hyaluronic acid.Drug delivery · 2025Article
- Toward automated assessment of conjunctival hyperemia: A semisupervised artificial intelligence approach.Annals of the New York Academy of Sciences · 2025Article
- An Update on Novel Drug Delivery Systems for the Management of Glaucoma.Pharmaceutics · 2025Review
- Impact of Antiglaucoma Drug Number and Class on Corneal Epithelial Thickness Measured by OCT.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Bilateral In Vivo Confocal Microscopic Changes of the Corneal Subbasal Nerve Plexus in Patients with Acute Herpes Zoster Ophthalmicus.Ophthalmology and therapy · 2025Article
- Third-Generation Trabecular Micro-Bypass Implantation with Phacoemulsification for Glaucoma.Ophthalmology and therapy · 2025Article
- Associations between dementia and exposure to topical glaucoma medications.Journal of Alzheimer's disease : JAD · 2025Article
- Management of ocular adverse reactions to antiglaucoma medications-Survey of optometrists in Ghana.PLOS global public health · 2025Article
- Systemic adverse drug events to topical prostaglandin analogs for treating glaucoma: a retrospective focused pharmacovigilance study.BMC ophthalmology · 2024Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glaucoma is a chronic, progressive disease in which retinal ganglion cells disappear and subsequent, gradual reductions in the visual field ensues. Glaucoma eye drops have hypotensive effects and like all other medications are associated with adverse effects. Adverse reactions may either result from the main agent or from preservatives used in the drug vehicle. The preservative benzalkonium chloride, is one such compound that causes frequent adverse reactions such as superficial punctate keratitis, corneal erosion, conjunctival allergy, and conjunctival injection. Adverse reactions related to main hypotensive agents have been divided into those affecting the eye and those affecting the entire body. In particular, β-blockers frequently cause systematic adverse reactions, including bradycardia, decrease in blood pressure, irregular pulse and asthma attacks. Prostaglandin analogs have distinctive local adverse reactions, including eyelash bristling/lengthening, eyelid pigmentation, iris pigmentation, and upper eyelid deepening. No systemic adverse reactions have been linked to prostaglandin analog eye drop usage. These adverse reactions may be minimized when they are detected early and prevented by reducing the number of different eye drops used (via fixed combination eye drops), reducing the number of times eye drops are administered, using benzalkonium chloride-free eye drops, using lower concentration eye drops, and providing proper drop instillation training. Additionally, a one-time topical medication can be given to patients to allow observation of any adverse reactions, thereafter the preparation of a topical medication with the fewest known adverse reactions can be prescribed. This does require precise patient monitoring and inquiries about patient symptoms following medication use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.